Processa Pharmaceuticals Inc expected to post a loss of 32 cents a share - Earnings Preview

Processa Pharmaceuticals

28/03/2023 22:03

* Processa Pharmaceuticals Inc  PCSA.OQ   PCSA.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 30. 
    * 
    * ​Refinitiv's mean analyst estimate for Processa
Pharmaceuticals
Inc is for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Processa
Pharmaceuticals Inc is $5​, above​ its last closing price
of $0.45. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.34       -0.34      -0.37     Missed  -9.9
 Jun. 30 2022  -0.21       -0.20      -0.32     Missed  -57.4
 Mar. 31 2022  -0.21       -0.21      -0.20     Beat    6.2​
 Dec. 31 2021  -0.18       -0.19      -0.21     Missed  -10.5
 ​​Sep.        -0.18       -0.18      -0.19     Missed  -3.6
 30 2021                                                
 Jun. 30 2021  -0.14       -0.14      -0.20     Missed  -39.5​
 Mar. 31 2021  -0.10       -0.10      -0.14     Missed  -33.3
 Dec. 31 2020  -0.16       -0.35      -1.69     Missed  -376.1
 This summary was machine generated March 28 at 21:03 GMT.  All
figures in US dollars  unless otherwise stated